Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5792800
Reference Type
Journal Article
Subtype
Review
Title
Prodrugs: design and clinical applications
Author(s)
Rautio, J; Kumpulainen, H; Heimbach, T; Oliyai, R; Oh, D; Järvinen, T; Savolainen, J
Year
2008
Is Peer Reviewed?
1
Journal
Nature Reviews. Drug Discovery
ISSN:
1474-1776
EISSN:
1474-1784
Volume
7
Issue
3
Page Numbers
255-270
Language
English
PMID
18219308
DOI
10.1038/nrd2468
Web of Science Id
WOS:000253778200016
Abstract
Prodrugs are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. In both drug discovery and development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents. About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend. To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity